tuberous sclerosis complex

GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory

The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.